The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly

References

• AbramsPHThe standardization of terminology of lower urinary tract function: Report from the standardization sub-committee of the International Continence SocietyNeurourol Urodyn20022116717811857671
   PubMed Web of Science ®Google Scholar
• MooreCKGoldmanHBThe bladder epithelium and overactive bladder: what we knowCurr Urol Rep20067644744917052439
   PubMedGoogle Scholar
• IrwinDEPopulation-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC studyEur Urol200650613061314discussion 1314–1315.17049716
   PubMed Web of Science ®Google Scholar
• AnderssonKEMechanisms of disease: central nervous system involvement in overactive bladder syndromeNat Clin Pract Urol20041210310816474523
   PubMedGoogle Scholar
• AnderssonKELUTS treatment: future treatment optionsNeurourol Urodyn2007266 Suppl93494717696154
   PubMed Web of Science ®Google Scholar
• NortonPADistress and delay associated with urinary incontinence, frequency, and urgency in womenBMJ19882976657118711893144344
   PubMed Web of Science ®Google Scholar
• AbramsPOveractive bladder significantly affects quality of lifeAm J Manag Care2000611 SupplS580S59011183901
   PubMed Web of Science ®Google Scholar
• JohannessonMWillingness to pay for reduced incontinence symptomsBr J Urol19978045575629352692
   PubMedGoogle Scholar
• BrownJSUrinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research GroupJ Am Geriatr Soc200048772172510894308
   PubMed Web of Science ®Google Scholar
• WaggACohenMMedical therapy for the overactive bladder in the elderlyAge Ageing200231424124612147560
   PubMed Web of Science ®Google Scholar
• CaulfieldMPBirdsallNJInternational union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptorsPharmacol Rev1998502792909647869
   PubMed Web of Science ®Google Scholar
• WaggARecent advances in the treatment of urinary incontinence in older womenCurr Opin Urol200818438338818520759
   PubMed Web of Science ®Google Scholar
• WaggACurrent and future trends in the managment of overactive bladderInt Urogynecol J Pelvic Floor Dysfunct2007181819417061028
   PubMed Web of Science ®Google Scholar
• ChughtaiBChoice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacinClin Interv Aging20083350350918982920
   PubMed Web of Science ®Google Scholar
• TappAJThe treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled studyBr J Obstet Gynaecol19909765215262198921
   PubMedGoogle Scholar
• TodorovaAEffects of tolterodine, trospium chloride, and oxybutynin on the central nervous systemJ Clin Pharmacol200141663664411402632
   PubMed Web of Science ®Google Scholar
• WaldeckKComparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid glandJ Urol19971573109310979072550
   PubMed Web of Science ®Google Scholar
• GuptaSKSathyanGPharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutyninJ Clin Pharmacol199939328929610073329
   PubMed Web of Science ®Google Scholar
• HoCTransdermally-delivered oxybutynin (Oxytrol(R) for overactive bladderIssues Emerg Health Technol2001241411776281
   PubMedGoogle Scholar
• DmochowskiRRStaskinDRAdvances in drug delivery: improved bioavailability and drug effectCurr Urol Rep20023643944412425864
   PubMedGoogle Scholar
• NilvebrantLTolterodine – a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical dataLife Sci19976013–14112911369121357
   PubMed Web of Science ®Google Scholar
• AbramsPTolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladderBr J Urol19988168018109666761
   PubMedGoogle Scholar
• DrutzHPClinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladderInt Urogynecol J Pelvic Floor Dysfunct199910528328910543335
   PubMedGoogle Scholar
• Malone-LeeJGTolterodine: a safe and effective treatment for older patients with overactive bladderJ Am Geriatr Soc200149670070511454106
   PubMed Web of Science ®Google Scholar
• Van KerrebroeckPTolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladderUrology200157341442111248608
   PubMed Web of Science ®Google Scholar
• KelleherCJLong-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladderAm J Manag Care2002819 SupplS616S63012516956
   PubMed Web of Science ®Google Scholar
• KelleherCJHealth-related quality of life of patients receiving extended-release tolterodine for overactive bladderAm J Manag Care2002819 SupplS608S61512516955
   PubMed Web of Science ®Google Scholar
• KayGDifferential effects of the antimuscarinic agents tolterodine tartrate er and oxybutynin chloride er on recent memory in older subjectsProceedings of the 2006 meeting of the International Continence Society2006P087
   Google Scholar
• KayGDifferential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjectsEur Urol200650231732616687205
   PubMed Web of Science ®Google Scholar
• ChappleCRRandomized, double-blind placebo- and tolterodinecontrolled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU Int200493330331014764127
   PubMed Web of Science ®Google Scholar
• ChappleCRA comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trialEur Urol200548346447015990220
   PubMed Web of Science ®Google Scholar
• DioknoACProspective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trialMayo Clin Proc200378668769512934777
   PubMed Web of Science ®Google Scholar
• AndersonRUEffectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladderInt Urogynecol J Pelvic Floor Dysfunct200617550251116724169
   PubMed Web of Science ®Google Scholar
• DmochowskiRRComparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinenceUrology200362223724212893326
   PubMed Web of Science ®Google Scholar
• KaplanSATolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trialJAMA2006296192319232817105794
   PubMed Web of Science ®Google Scholar
• TsengLHRandomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndromeNeurourol Urodyn2009281475119089890
   PubMed Web of Science ®Google Scholar